Sonde Health has acquired NeuroLex Laboratories in a move aimed at refining its voice-based healthcare platform.
Sonde Health specializes in what it calls “vocal biomarker” technology, which is designed to analyze snippets of speech to look for signs of illness. While the technology doesn’t offer a robust diagnostic tool in itself, it can be used as an early warning system for various symptoms.
NeuroLex Laboratories, meanwhile, is known for its voice-based survey and data acquisition platform, designed to operate over the web. In acquiring NeuroLex and its platform, Sonde Health appears to be primarily interested in its attendant database of voice samples, explaining in a statement that combining it with Sonde’s own database “forms one of the world’s preeminent biobanks focused on vocal biomarkers.”
Sonde Health also noted that NeuroLex’s web-based platform will expand its reach beyond the mobile channel in which Sonde has been operating.
“Incorporating NeuroLex’s impressive work in voice-based surveys and research moves us significantly forward in becoming the one-stop shop for health condition detection and monitoring through voice,” explained Sonde Health CEO David Liu. “NeuroLex’s voice-based survey platform and biobank will accelerate our research and development, and our collection and analysis of high-quality voice data, bolstering all the products we provide to our customers.”
Financial terms of the acquisition have not been announced, but Sonde Health did indicate that Jim Schwoebel, the CEO of NeuroLex, will now join the executive team of Sonde Health, in the role of VP of Data and Research.
For his part, Schwoebel explained that his team started NeuroLex to create a voice test that would help screen for psychosis and related psychiatric conditions, and said that the integration with Sonde will allow his team to expand their efforts beyond those conditions. “I’m beyond excited to join Sonde’s amazing team and mission,” he said.
August 25, 2020 – by Alex Perala